{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:54:57Z","timestamp":1767664497527},"reference-count":25,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T00:00:00Z","timestamp":1210809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the safety, immunological outcome and HIV\u20101 evolution in the reverse transcriptase (RT) in patients with multidrug resistance receiving zidovudine\/lamivudine\/abacavir (TZV) plus tenofovir (TDF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pilot analysis of highly experienced patients (<jats:italic>n<\/jats:italic>=28), with \u22651 thymidine\u2010associated mutation (TAM) and the M184V mutation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median of 8.5 treatment regimens, 58% Centers for Disease Control stage C. Baseline (nadir) CD4 count 363 (112)\u2003cells\/\u03bcL. There was a sustained 24\u2010week drop in viral load (VL) of 0.71 HIV\u20101 RNA copies\/mL (<jats:italic>P<\/jats:italic>&lt;0.001), with 35.7% (10\/28) achieving a VL of &lt;50\u2003copies\/mL. The median 24\u2010week decrease in CD4 was \u221253\u2003cells\/\u03bcL and only \u221217\u2003cells\/\u03bcL when baseline CD4 was &lt;350\u2003cells\/\u03bcL. There was no evolution in RT mutations, TAMs, accessory mutations or K65R. No clinical progression and one out of 28 suspected abacavir Hypersensitivity Reaction (HSR). Lower probability of achieving VL&lt;400\u2003copies\/mL was associated with D67N (<jats:italic>P<\/jats:italic>=0.007), D67N\/M41L (<jats:italic>P<\/jats:italic>=0.01), \u22653 TAMs (<jats:italic>P<\/jats:italic>=0.07) and VL&gt;10\u2003000\u2003copies\/mL (<jats:italic>P<\/jats:italic>=0.01). Mutations conferring zidovudine hypersusceptibility (Y181C, K65R and L74V) did not improve virological or immunological outcomes. Better CD4 outcomes were seen in patients without M41L (<jats:italic>P<\/jats:italic>=0.04) or with baseline VL&lt;10\u2003000\u2003copies\/mL (<jats:italic>P<\/jats:italic>=0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A bridging regimen with TZV+TDF prevents significant immunological decline and may forestall viral evolution in HIV\u20101 RT despite persistent viral replication.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2008.00581.x","type":"journal-article","created":{"date-parts":[[2008,5,16]],"date-time":"2008-05-16T01:12:48Z","timestamp":1210900368000},"page":"508-513","source":"Crossref","is-referenced-by-count":6,"title":["Targeting only reverse transcriptase with zidovudine\/lamivudine\/abacavir plus tenofovir in HIV\u20101\u2010infected patients with multidrug\u2010resistant virus: a multicentre pilot study"],"prefix":"10.1111","volume":"9","author":[{"given":"JM","family":"Llibre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bonjoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Iribarren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MJ","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Negredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"P\u00e9rez\u2010Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Martinez\u2010Picado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Schapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the HIV Conference Call study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,8,12]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the Use of Antiretroviral Agents in HIV\u20101 Infected Adults and Adolescents. Available at:http:\/\/aidsinfo.nih.gov."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131358.29586.6b"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280141fdf"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/521937"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102153440702"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062360"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328011033a"},{"key":"e_1_2_5_9_2","first-page":"795","article-title":"Lamivudine monotherapy in HIV\u20101\u2010infected patients harbouring a lamivudine\u2010resistant virus","volume":"20","author":"Castagna A","year":"2006","journal-title":"a randomized pilot study (E-184V Study)"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00017"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/496892"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000137005.63376.6e"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/378281"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000189851.21441.f1"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2254-2256.2002"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.16.8621-8632.2003"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3281ac229b"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/135965350701200514","article-title":"Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV","volume":"12","author":"Sturmer M","year":"2007","journal-title":"Antiviral Ther"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.10.4971-4977.2006"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280187505"},{"key":"e_1_2_5_21_2","first-page":"22","article-title":"K65R, TAMs and tenofovir","volume":"6","author":"Miller MD.","year":"2004","journal-title":"AIDS Rev"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000131355.44834.e4"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/135965350601100211","article-title":"Low genetic barrier to large increases in HIV\u20101 cross\u2010resistance to protease inhibitors during salvage therapy","volume":"11","author":"Morand\u2010Joubert L","year":"2006","journal-title":"Antiviral Ther"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200412150-00009"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki170"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000216369.30948.18"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2008.00581.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2008.00581.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:55:29Z","timestamp":1696877729000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2008.00581.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1468-1293.2008.00581.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00581.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}